Skip to main content

Table 1 Summary of clinical studies for model development and test application

From: Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma

StudyTreatmentDose and schedulePatient numbera
(total treated)
Analysis
CheckMate 009 (NCT01358721), phase I dose escalationNivolumab0.3, 2, and 10.0 mg/kg, Q3WN = 89 (91)Training dataset
CheckMate 025 (NCT01668784), phase IIINivolumab3.0 mg/kg, Q2WN = 391 (406)Training dataset
Everolimus10.0 mg as a daily doseN = 297 (397)Test dataset
CheckMate 010 (NCT01354431), phase II dose rangingNivolumab0.3, 2, and 10.0 mg/kg, Q3WN = 156 (167)Test dataset
  1. aPatients missing cytokine or pharmacokinetics data were excluded from the training and test datasets of the machine-learning model. Q2W every 2 weeks, Q3W every 3 weeks